Head-to-head effectiveness and safety of pembrolizumab plus axitinib vs. nivolumab plus ipilimumab in metastatic renal cell carcinoma in the United States.

被引：0
|
作者：
Aran, Dvir
Granot-Hershkovitz, Einat
Amar-Farkash, Shlomit
Rosenberg-Katz, Keren
机构：
[1] Technion Israel Inst Technol, Fac Biol, Haifa, Israel
[2] Carelon Digital Platforms, Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4532
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI) VS PEMBROLIZUMAB PLUS AXITINIB (PEM plus AXI) FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE OR POOR (I/P)-RISK ADVANCED RENAL CELL CARCINOMA PATIENTS IN PERU
    Youn, J. H.
    Jain, D.
    Guiot, V
    Velarde, J.
    Garcia, Perlaza J.
    Dyer, M.
    VALUE IN HEALTH, 2024, 27 (06) : S142 - S142
  • [22] Real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States.
    Zakharia, Yousef
    Thomaidou, Despina
    Li, Benjamin
    Siu, Gordan
    Levin, Rebecca
    Vlahiotis, Anna
    Zanotti, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [23] Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
    Numakura, Kazuyuki
    Sekine, Yuya
    Hatakeyama, Shingo
    Muto, Yumina
    Sobu, Ryuta
    Kobayashi, Mizuki
    Sasagawa, Hajime
    Kashima, Soki
    Yamamto, Ryohei
    Nara, Taketoshi
    Akashi, Hideo
    Tabata, Ryuji
    Sato, Satoshi
    Saito, Mitsuru
    Narita, Shintaro
    Ohyama, Chikara
    Habuchi, Tomonori
    CANCER MEDICINE, 2023, 12 (16): : 16837 - 16845
  • [24] Pembrolizumab plus lenvatinib vs nivolumab plus cabozantinib in patients with metastatic renal cell carcinoma: A matching adjusted indirect comparison (MAIC).
    Rane, Pratik
    Walton, Laura
    Schmidinger, Manuela
    Peer, Avivit
    Mt-Isa, Shahrul
    Burgents, Joseph E.
    Sundaram, Murali
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 399 - 399
  • [25] A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma
    Kato, Renpei
    Kojima, Takahiro
    Sazuka, Tomokazu
    Yamamoto, Hayato
    Fukuda, Shohei
    Yamana, Kazutoshi
    Sugino, Yusuke
    Hamamoto, Shuzo
    Nakaigawa, Noboru
    Kabu, Koki
    Murakami, Hiroshi
    Obara, Wataru
    ANTICANCER RESEARCH, 2021, 41 (12) : 6199 - 6209
  • [26] Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck The Phase 2 CheckMate 714 Randomized Clinical Trial
    Harrington, Kevin J.
    Ferris, Robert L.
    Gillison, Maura
    Tahara, Makoto
    Argiris, Athanasios
    Fayette, Jerome
    Schenker, Michael
    Bratland, Ase
    Walker, John W. T.
    Grell, Peter
    Even, Caroline
    Chung, Christine H.
    Redman, Rebecca
    Coutte, Alexandre
    Salas, Sebastien
    Grant, Cliona
    de Azevedo, Sergio
    Soulieres, Denis
    Hansen, Aaron R.
    Wei, Li
    Khan, Tariq Aziz
    Miller-Moslin, Karen
    Roberts, Mustimbo
    Haddad, Robert
    JAMA ONCOLOGY, 2023, 9 (06) : 779 - 789
  • [27] Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients
    Thana, Myuran
    Basappa, Naveen S.
    Ghosh, Sunita
    Kollmannsberger, Christian K.
    Heng, Daniel Y. C.
    Hansen, Aaron R.
    Graham, Jeffery
    Soulieres, Denis
    Reaume, Martin Neil
    Lalani, Aly-Khan A.
    Castonguay, Vincent
    Bjarnason, Georg A.
    Patenaude, Francois
    Breau, Rodney H.
    Pouliot, Frederic
    Kapoor, Anil
    Wood, Lori A.
    CLINICAL GENITOURINARY CANCER, 2022, 20 (03) : 210 - 218
  • [28] Hypopituitarism induced by pembrolizumab plus axitinib in the treatment of metastatic renal cell carcinoma: A case report
    Hanawa, Kazushi
    Sawada, Norifumi
    Aikawa, Junki
    Otake, Yuko
    Kasai, Yoshifumi
    Mochizuki, Keito
    Shimura, Hiroshi
    Mochizuki, Takanori
    Kira, Satoru
    Mitsui, Takahiko
    ONCOLOGY LETTERS, 2024, 27 (02)
  • [29] Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
    Zhang, Yue
    Wu, Shenhong
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S585 - S588
  • [30] GRADE 3/4 ADVERSE EVENT (AE) COSTS OF NIVOLUMAB PLUS IPILIMUMAB (N plus I) VERSUS NIVOLUMAB PLUS CABOZANTINIB (N plus C) AND PEMBROLIZUMAB PLUS AXITINIB (P plus A) FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA (ARCC)
    McGregor, B.
    Geynisman, D.
    Burotto, M.
    Porta, C.
    Suarez, C.
    Bourlon, M. T.
    Stwalley, B.
    Du, E. X.
    Gu, C.
    Sendhil, S.
    Betts, K. A.
    Huo, S.
    Choueiri, T. K.
    VALUE IN HEALTH, 2021, 24 : S28 - S29
12345